CDK4 and glioblastoma: Previous preclinical studies have shown that a combination of CDK4/6 inhibitors, palbociclib, or abemaciclib with everolimus or altiratinib resulted in longer OS than treatment with CDK4/6 inhibitors alone in glioblastoma mouse models [15,17].